SOD1 and Parkinson disease: These positive results, together with the ability of CuII-ATSM to accumulate in PD-relevant tissues, with the aforementioned purported role of SOD1 in the pathogenesis of PD and with the fact the CuII-ATSM is able to stimulate SOD1 activity, represent the rationale for a phase 1 clinical trial based on the use of CuII-ATSM, which is currently in progress (NCT03204929).